Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome

MeSH terms

• Antirheumatic Agents / administration & dosage
• Betacoronavirus / isolation & purification
• Biomarkers, Pharmacological
• COVID-19
• Coronavirus Infections* / immunology
• Coronavirus Infections* / physiopathology
• Coronavirus Infections* / therapy
• Cytokine Release Syndrome* / blood
• Cytokine Release Syndrome* / diagnosis
• Cytokine Release Syndrome* / drug therapy
• Cytokine Release Syndrome* / etiology
• Dose-Response Relationship, Drug
• Drug Monitoring / methods
• Ferritins / blood
• Humans
• Interleukin 1 Receptor Antagonist Protein / administration & dosage*
• Interleukin-6 / blood*
• Lactate Dehydrogenases / blood
• Male
• Middle Aged
• Pandemics*
• Pneumonia, Viral* / immunology
• Pneumonia, Viral* / physiopathology
• Pneumonia, Viral* / therapy
• Respiration, Artificial / methods
• SARS-CoV-2
• Severity of Illness Index
• Treatment Outcome